hydrogen carbonate has been researched along with Hyperphosphatemia in 9 studies
Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.
hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bixalomer (Bix) is an amine-functional polymer, non-calcium-containing phosphate (P) binder, and has been clinically available in Japan recently." | 5.40 | Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. ( Ito, K; Kumata, C; Matsuzaka, K; Nakajima, Y; Ogata, H; Shishido, K; Takeshima, A; Wakasa, M, 2014) |
| "Hyperphosphatemia is highly prevalent in patients with chronic kidney disease (CKD), particularly in those with advanced or end-stage renal disease." | 2.45 | Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. ( Pai, AB; Shepler, BM, 2009) |
| "Bixalomer (Bix) is an amine-functional polymer, non-calcium-containing phosphate (P) binder, and has been clinically available in Japan recently." | 1.40 | Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms. ( Ito, K; Kumata, C; Matsuzaka, K; Nakajima, Y; Ogata, H; Shishido, K; Takeshima, A; Wakasa, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quiñones, H | 1 |
| Hamdi, T | 1 |
| Sakhaee, K | 1 |
| Pasch, A | 1 |
| Moe, OW | 1 |
| Pak, CYC | 1 |
| Darmon, M | 1 |
| Vincent, F | 1 |
| Camous, L | 1 |
| Canet, E | 1 |
| Bonmati, C | 1 |
| Braun, T | 1 |
| Caillot, D | 1 |
| Cornillon, J | 1 |
| Dimicoli, S | 1 |
| Etienne, A | 1 |
| Galicier, L | 1 |
| Garnier, A | 1 |
| Girault, S | 1 |
| Hunault-Berger, M | 1 |
| Marolleau, JP | 1 |
| Moreau, P | 1 |
| Raffoux, E | 1 |
| Recher, C | 1 |
| Thiebaud, A | 1 |
| Thieblemont, C | 1 |
| Azoulay, E | 1 |
| Bezzaoucha, S | 2 |
| Pichette, V | 2 |
| Lafrance, JP | 2 |
| Bell, R | 2 |
| Laurin, LP | 1 |
| Vallée, M | 2 |
| Wilson, FP | 1 |
| Berns, JS | 1 |
| Ito, K | 1 |
| Takeshima, A | 1 |
| Shishido, K | 1 |
| Wakasa, M | 1 |
| Kumata, C | 1 |
| Matsuzaka, K | 1 |
| Nakajima, Y | 1 |
| Ogata, H | 1 |
| Beaubien-Souligny, W | 1 |
| Lamarche, C | 1 |
| Ouimet, D | 1 |
| Pai, AB | 1 |
| Shepler, BM | 1 |
| Caravaca, F | 1 |
| Villa, J | 1 |
| García de Vinuesa, E | 1 |
| Martínez del Viejo, C | 1 |
| Martínez Gallardo, R | 1 |
| Macías, R | 1 |
| Ferreira, F | 1 |
| Cerezo, I | 1 |
| Hernández-Gallego, R | 1 |
| Ketteler, M | 1 |
| Rix, M | 1 |
| Fan, S | 1 |
| Pritchard, N | 1 |
| Oestergaard, O | 1 |
| Chasan-Taber, S | 1 |
| Heaton, J | 1 |
| Duggal, A | 1 |
| Kalra, PA | 1 |
2 reviews available for hydrogen carbonate and Hyperphosphatemia
| Article | Year |
|---|---|
Tumor lysis syndrome: new challenges and recent advances.
Topics: Acute Kidney Injury; Allopurinol; Bicarbonates; Buffers; Calcium; Diuretics; Enzyme Inhibitors; Febu | 2014 |
Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Topics: Acidosis; Animals; Bicarbonates; Chelating Agents; Chemistry, Pharmaceutical; Clinical Trials as Top | 2009 |
2 trials available for hydrogen carbonate and Hyperphosphatemia
| Article | Year |
|---|---|
Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
Topics: Acid-Base Equilibrium; Acidosis; Aged; Bicarbonates; Biomarkers; Calcium Citrate; Cardiovascular Dis | 2019 |
Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.
Topics: Aged; Australia; Bicarbonates; Biomarkers; Calcium; Chelating Agents; Cholesterol, LDL; Chronic Dise | 2008 |
5 other studies available for hydrogen carbonate and Hyperphosphatemia
| Article | Year |
|---|---|
Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Topics: Acute Kidney Injury; Adult; Aged; Allopurinol; Bicarbonates; Biomarkers; Comorbidity; Disease-Free S | 2013 |
The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis.
Topics: Acidosis; Bicarbonates; Chelating Agents; Humans; Hyperphosphatemia; Polyamines; Renal Dialysis; Ret | 2013 |
Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
Topics: Abdominal Pain; Bicarbonates; Calcium; Chelating Agents; Cohort Studies; Constipation; Female; Follo | 2014 |
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Topics: Acidosis; Bicarbonates; Canada; Chelating Agents; Disease Progression; Drug Monitoring; Female; Huma | 2015 |
Relationship between serum phosphorus and the progression of advanced chronic kidney disease.
Topics: Aged; Bicarbonates; Biomarkers; Calcitriol; Calcium; Chelating Agents; Chronic Disease; Confounding | 2011 |